Anvatabart opadotin is a monoclonal antibody conjugated commercialized by Ambrx Biopharma, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to Globaldata, it is involved in 14 clinical trials, of which 2 were completed, 10 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Anvatabart opadotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Anvatabart opadotin is expected to reach an annual total of $108 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Anvatabart opadotin Overview
Anvatabart opadotin (ARX-788) is under development for the treatment of Her2-positive advanced and HER2 low expressing metastatic breast cancer, gastroesophageal junction adenocarcinoma, esophageal cancer, salivary gland cancer, endometrial cancer, metastatic biliary tract cancer, GE junction carcinoma, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic pancreatic cancer and gastric cancer. It is administered through intravenous route. The drug candidate is an HER2 specific monoclonal antibody conjugated with Amberstatin 269. The drug candidate is developed based on site-specific conjugation technology.
It was also under development for the treatment of colon cancer, pancreatic cancer, ovarian cancer.
Ambrx Biopharma Overview
Ambrx Biopharma (Ambrx) is a clinical stage biopharmaceutical company that develops anti-body drug conjugates (ADC) and therapies to modulate immune system. The company is developing ARX 788, an anti-HER2 ADC for treatment in areas of breast cancer, gastric cancer, and other solid tumors. Its pipeline product also includes ARX 517 program that targets prostate-specific membrane antigen to treat prostate cancer; and ARX305 for treatment of renal cell carcinoma (RCC), nasopharyngeal cancers, multiple myeloma, non-Hodgkin’s lymphoma, and acute myeloid leukemia (AML). Ambrx works in collaboration with Zhejiang Medicine, Sino Biopharmaceutical, and BeiGene. The company is conducting its ADCs clinical trials in China, and the US. Ambrx is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$7.4 million for the fiscal year ended December 2022 (FY2022), a decrease of 0.7% over FY2021. The operating loss of the company was US$76.4 million in FY2022, compared to an operating loss of US$64.4 million in FY2021. The net loss of the company was US$78 million in FY2022, compared to a net loss of US$68.1 million in FY2021.
The company reported revenues of US$0.1 million for the third quarter ended September 2023, a decrease of 95.3% over the previous quarter.
For a complete picture of Anvatabart opadotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
